2018 AANS Annual Scientific Meeting-GBM Clinical Trials with Viral Based Gene Therapies: Resurrection of an Old Paradigm

GBM Clinical Trials with Viral Based Gene Therapies: Resurrection of an Old Paradigm

Video Transcription

Video Summary

In this video, Dr. Chioka discusses gene therapy and viral-based gene therapies for treating glioblastoma (GBM). He explains the use of replication-defective viruses as vectors to deliver anticancer genes, such as thymidine kinase, to make cancer cells sensitive to drugs. He references previous clinical trials using retroviral vectors and discusses their limitations. Dr. Chioka presents the results of a recent Phase II study using gene-mediated cytotoxic immunotherapy in newly diagnosed GBM patients, showing a significant increase in median survival time compared to standard care alone. He also discusses another study using an adenoviral vector to deliver interleukin-12 and its potential benefits.

Asset Caption

E. Antonio Chiocca, MD, PhD, FAANS

Keywords

gene therapy

viral-based gene therapies

glioblastoma

replication-defective viruses

anticancer genes